The global market for Fusion Protein Biosimilars was valued at US$ 2623 million in the year 2024 and is projected to reach a revised size of US$ 5941 million by 2031, growing at a CAGR of 12.5% during the forecast period.

Fusion Protein Biosimilars Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Fusion Protein Biosimilars competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Fusion Protein BiosimilarsIn 2024, global Fusion Protein Biosimilars production reached approximately 12 million units (doses/vials), with an average global market price of around US$ 220 per unit.Fusion Protein Biosimilars are biologic medicines designed to be highly similar to approved reference fusion protein drugs, such as etanercept, used for autoimmune diseases and oncology. They combine therapeutic proteins with functional domains to improve efficacy, stability, or targeting.

North American market for Fusion Protein Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Fusion Protein Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Fusion Protein Biosimilars include Samsung Bioepis, Amgen Inc., Pfizer Inc., Sandoz (Novartis Division), Coherus BioSciences, Celltrion Healthcare, Biocon Biologics, Dr. Reddy’s Laboratories, Mylan (Viatris Inc.), 3SBio Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Fusion Protein Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fusion Protein Biosimilars.

The Fusion Protein Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Fusion Protein Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Fusion Protein Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Fusion Protein Biosimilars Market Report

Report Metric	Details
Report Name	Fusion Protein Biosimilars Market
Accounted market size in year	US$ 2623 million
Forecasted market size in 2031	US$ 5941 million
CAGR	12.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cytokines Recombinant Protein Immunoglobin (Ig) Fusion Protein
Segment by Application	Hospitals Research Institute
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Samsung Bioepis, Amgen Inc., Pfizer Inc., Sandoz (Novartis Division), Coherus BioSciences, Celltrion Healthcare, Biocon Biologics, Dr. Reddy’s Laboratories, Mylan (Viatris Inc.), 3SBio Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Fusion Protein Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Fusion Protein Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Fusion Protein Biosimilars Market growing?

Ans: The Fusion Protein Biosimilars Market witnessing a CAGR of 12.5% during the forecast period 2025-2031.

What is the Fusion Protein Biosimilars Market size in 2031?

Ans: The Fusion Protein Biosimilars Market size in 2031 will be US$ 5941 million.

Who are the main players in the Fusion Protein Biosimilars Market report?

Ans: The main players in the Fusion Protein Biosimilars Market are Samsung Bioepis, Amgen Inc., Pfizer Inc., Sandoz (Novartis Division), Coherus BioSciences, Celltrion Healthcare, Biocon Biologics, Dr. Reddy’s Laboratories, Mylan (Viatris Inc.), 3SBio Inc.

What are the Application segmentation covered in the Fusion Protein Biosimilars Market report?

Ans: The Applications covered in the Fusion Protein Biosimilars Market report are Hospitals, Research Institute

What are the Type segmentation covered in the Fusion Protein Biosimilars Market report?

Ans: The Types covered in the Fusion Protein Biosimilars Market report are Cytokines Recombinant Protein, Immunoglobin (Ig) Fusion Protein

1 Fusion Protein Biosimilars Market Overview

1.1 Product Definition

1.2 Fusion Protein Biosimilars by Type

1.2.1 Global Fusion Protein Biosimilars Market Value Comparison by Type (2024 VS 2031)

1.2.2 Cytokines Recombinant Protein

1.2.3 Immunoglobin (Ig) Fusion Protein

1.3 Fusion Protein Biosimilars by Application

1.3.1 Global Fusion Protein Biosimilars Market Value by Application (2024 VS 2031)

1.3.2 Hospitals

1.3.3 Research Institute

1.4 Global Fusion Protein Biosimilars Market Size Estimates and Forecasts

1.4.1 Global Fusion Protein Biosimilars Revenue 2020-2031

1.4.2 Global Fusion Protein Biosimilars Sales 2020-2031

1.4.3 Global Fusion Protein Biosimilars Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Fusion Protein Biosimilars Market Competition by Manufacturers

2.1 Global Fusion Protein Biosimilars Sales Market Share by Manufacturers (2020-2025)

2.2 Global Fusion Protein Biosimilars Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Fusion Protein Biosimilars Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Fusion Protein Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Fusion Protein Biosimilars, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Fusion Protein Biosimilars, Product Type & Application

2.7 Global Key Manufacturers of Fusion Protein Biosimilars, Date of Enter into This Industry

2.8 Global Fusion Protein Biosimilars Market Competitive Situation and Trends

2.8.1 Global Fusion Protein Biosimilars Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Fusion Protein Biosimilars Players Market Share by Revenue

2.8.3 Global Fusion Protein Biosimilars Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Fusion Protein Biosimilars Market Scenario by Region

3.1 Global Fusion Protein Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Fusion Protein Biosimilars Sales by Region: 2020-2031

3.2.1 Global Fusion Protein Biosimilars Sales by Region: 2020-2025

3.2.2 Global Fusion Protein Biosimilars Sales by Region: 2026-2031

3.3 Global Fusion Protein Biosimilars Revenue by Region: 2020-2031

3.3.1 Global Fusion Protein Biosimilars Revenue by Region: 2020-2025

3.3.2 Global Fusion Protein Biosimilars Revenue by Region: 2026-2031

3.4 North America Fusion Protein Biosimilars Market Facts & Figures by Country

3.4.1 North America Fusion Protein Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Fusion Protein Biosimilars Sales by Country (2020-2031)

3.4.3 North America Fusion Protein Biosimilars Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Fusion Protein Biosimilars Market Facts & Figures by Country

3.5.1 Europe Fusion Protein Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Fusion Protein Biosimilars Sales by Country (2020-2031)

3.5.3 Europe Fusion Protein Biosimilars Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Fusion Protein Biosimilars Market Facts & Figures by Region

3.6.1 Asia Pacific Fusion Protein Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Fusion Protein Biosimilars Sales by Region (2020-2031)

3.6.3 Asia Pacific Fusion Protein Biosimilars Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Fusion Protein Biosimilars Market Facts & Figures by Country

3.7.1 Latin America Fusion Protein Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Fusion Protein Biosimilars Sales by Country (2020-2031)

3.7.3 Latin America Fusion Protein Biosimilars Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Fusion Protein Biosimilars Market Facts & Figures by Country

3.8.1 Middle East and Africa Fusion Protein Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Fusion Protein Biosimilars Sales by Country (2020-2031)

3.8.3 Middle East and Africa Fusion Protein Biosimilars Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Fusion Protein Biosimilars Sales by Type (2020-2031)

4.1.1 Global Fusion Protein Biosimilars Sales by Type (2020-2025)

4.1.2 Global Fusion Protein Biosimilars Sales by Type (2026-2031)

4.1.3 Global Fusion Protein Biosimilars Sales Market Share by Type (2020-2031)

4.2 Global Fusion Protein Biosimilars Revenue by Type (2020-2031)

4.2.1 Global Fusion Protein Biosimilars Revenue by Type (2020-2025)

4.2.2 Global Fusion Protein Biosimilars Revenue by Type (2026-2031)

4.2.3 Global Fusion Protein Biosimilars Revenue Market Share by Type (2020-2031)

4.3 Global Fusion Protein Biosimilars Price by Type (2020-2031)

5 Segment by Application

5.1 Global Fusion Protein Biosimilars Sales by Application (2020-2031)

5.1.1 Global Fusion Protein Biosimilars Sales by Application (2020-2025)

5.1.2 Global Fusion Protein Biosimilars Sales by Application (2026-2031)

5.1.3 Global Fusion Protein Biosimilars Sales Market Share by Application (2020-2031)

5.2 Global Fusion Protein Biosimilars Revenue by Application (2020-2031)

5.2.1 Global Fusion Protein Biosimilars Revenue by Application (2020-2025)

5.2.2 Global Fusion Protein Biosimilars Revenue by Application (2026-2031)

5.2.3 Global Fusion Protein Biosimilars Revenue Market Share by Application (2020-2031)

5.3 Global Fusion Protein Biosimilars Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Samsung Bioepis

6.1.1 Samsung Bioepis Company Information

6.1.2 Samsung Bioepis Description and Business Overview

6.1.3 Samsung Bioepis Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Samsung Bioepis Fusion Protein Biosimilars Product Portfolio

6.1.5 Samsung Bioepis Recent Developments/Updates

6.2 Amgen Inc.

6.2.1 Amgen Inc. Company Information

6.2.2 Amgen Inc. Description and Business Overview

6.2.3 Amgen Inc. Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Amgen Inc. Fusion Protein Biosimilars Product Portfolio

6.2.5 Amgen Inc. Recent Developments/Updates

6.3 Pfizer Inc.

6.3.1 Pfizer Inc. Company Information

6.3.2 Pfizer Inc. Description and Business Overview

6.3.3 Pfizer Inc. Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pfizer Inc. Fusion Protein Biosimilars Product Portfolio

6.3.5 Pfizer Inc. Recent Developments/Updates

6.4 Sandoz (Novartis Division)

6.4.1 Sandoz (Novartis Division) Company Information

6.4.2 Sandoz (Novartis Division) Description and Business Overview

6.4.3 Sandoz (Novartis Division) Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sandoz (Novartis Division) Fusion Protein Biosimilars Product Portfolio

6.4.5 Sandoz (Novartis Division) Recent Developments/Updates

6.5 Coherus BioSciences

6.5.1 Coherus BioSciences Company Information

6.5.2 Coherus BioSciences Description and Business Overview

6.5.3 Coherus BioSciences Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Coherus BioSciences Fusion Protein Biosimilars Product Portfolio

6.5.5 Coherus BioSciences Recent Developments/Updates

6.6 Celltrion Healthcare

6.6.1 Celltrion Healthcare Company Information

6.6.2 Celltrion Healthcare Description and Business Overview

6.6.3 Celltrion Healthcare Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Celltrion Healthcare Fusion Protein Biosimilars Product Portfolio

6.6.5 Celltrion Healthcare Recent Developments/Updates

6.7 Biocon Biologics

6.7.1 Biocon Biologics Company Information

6.7.2 Biocon Biologics Description and Business Overview

6.7.3 Biocon Biologics Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Biocon Biologics Fusion Protein Biosimilars Product Portfolio

6.7.5 Biocon Biologics Recent Developments/Updates

6.8 Dr. Reddy’s Laboratories

6.8.1 Dr. Reddy’s Laboratories Company Information

6.8.2 Dr. Reddy’s Laboratories Description and Business Overview

6.8.3 Dr. Reddy’s Laboratories Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Dr. Reddy’s Laboratories Fusion Protein Biosimilars Product Portfolio

6.8.5 Dr. Reddy’s Laboratories Recent Developments/Updates

6.9 Mylan (Viatris Inc.)

6.9.1 Mylan (Viatris Inc.) Company Information

6.9.2 Mylan (Viatris Inc.) Description and Business Overview

6.9.3 Mylan (Viatris Inc.) Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Mylan (Viatris Inc.) Fusion Protein Biosimilars Product Portfolio

6.9.5 Mylan (Viatris Inc.) Recent Developments/Updates

6.10 3SBio Inc.

6.10.1 3SBio Inc. Company Information

6.10.2 3SBio Inc. Description and Business Overview

6.10.3 3SBio Inc. Fusion Protein Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.10.4 3SBio Inc. Fusion Protein Biosimilars Product Portfolio

6.10.5 3SBio Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Fusion Protein Biosimilars Industry Chain Analysis

7.2 Fusion Protein Biosimilars Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Fusion Protein Biosimilars Production Mode & Process Analysis

7.4 Fusion Protein Biosimilars Sales and Marketing

7.4.1 Fusion Protein Biosimilars Sales Channels

7.4.2 Fusion Protein Biosimilars Distributors

7.5 Fusion Protein Biosimilars Customer Analysis

8 Fusion Protein Biosimilars Market Dynamics

8.1 Fusion Protein Biosimilars Industry Trends

8.2 Fusion Protein Biosimilars Market Drivers

8.3 Fusion Protein Biosimilars Market Challenges

8.4 Fusion Protein Biosimilars Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Dr. Reddy’s Laboratories

3SBio Inc

Mylan (Viatris Inc.)

List of Tables

Table 1. Global Fusion Protein Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Fusion Protein Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Fusion Protein Biosimilars Market Competitive Situation by Manufacturers in 2024

Table 4. Global Fusion Protein Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Fusion Protein Biosimilars Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Fusion Protein Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Fusion Protein Biosimilars Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Fusion Protein Biosimilars Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Fusion Protein Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Fusion Protein Biosimilars, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Fusion Protein Biosimilars, Product Type & Application

Table 12. Global Key Manufacturers of Fusion Protein Biosimilars, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Fusion Protein Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fusion Protein Biosimilars as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Fusion Protein Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Fusion Protein Biosimilars Sales by Region (2020-2025) & (K Units)

Table 18. Global Fusion Protein Biosimilars Sales Market Share by Region (2020-2025)

Table 19. Global Fusion Protein Biosimilars Sales by Region (2026-2031) & (K Units)

Table 20. Global Fusion Protein Biosimilars Sales Market Share by Region (2026-2031)

Table 21. Global Fusion Protein Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Fusion Protein Biosimilars Revenue Market Share by Region (2020-2025)

Table 23. Global Fusion Protein Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Fusion Protein Biosimilars Revenue Market Share by Region (2026-2031)

Table 25. North America Fusion Protein Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Fusion Protein Biosimilars Sales by Country (2020-2025) & (K Units)

Table 27. North America Fusion Protein Biosimilars Sales by Country (2026-2031) & (K Units)

Table 28. North America Fusion Protein Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Fusion Protein Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Fusion Protein Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Fusion Protein Biosimilars Sales by Country (2020-2025) & (K Units)

Table 32. Europe Fusion Protein Biosimilars Sales by Country (2026-2031) & (K Units)

Table 33. Europe Fusion Protein Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Fusion Protein Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Fusion Protein Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Fusion Protein Biosimilars Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Fusion Protein Biosimilars Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Fusion Protein Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Fusion Protein Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Fusion Protein Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Fusion Protein Biosimilars Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Fusion Protein Biosimilars Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Fusion Protein Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Fusion Protein Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Fusion Protein Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Fusion Protein Biosimilars Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Fusion Protein Biosimilars Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Fusion Protein Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Fusion Protein Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Fusion Protein Biosimilars Sales (K Units) by Type (2020-2025)

Table 51. Global Fusion Protein Biosimilars Sales (K Units) by Type (2026-2031)

Table 52. Global Fusion Protein Biosimilars Sales Market Share by Type (2020-2025)

Table 53. Global Fusion Protein Biosimilars Sales Market Share by Type (2026-2031)

Table 54. Global Fusion Protein Biosimilars Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Fusion Protein Biosimilars Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Fusion Protein Biosimilars Revenue Market Share by Type (2020-2025)

Table 57. Global Fusion Protein Biosimilars Revenue Market Share by Type (2026-2031)

Table 58. Global Fusion Protein Biosimilars Price (US$/Unit) by Type (2020-2025)

Table 59. Global Fusion Protein Biosimilars Price (US$/Unit) by Type (2026-2031)

Table 60. Global Fusion Protein Biosimilars Sales (K Units) by Application (2020-2025)

Table 61. Global Fusion Protein Biosimilars Sales (K Units) by Application (2026-2031)

Table 62. Global Fusion Protein Biosimilars Sales Market Share by Application (2020-2025)

Table 63. Global Fusion Protein Biosimilars Sales Market Share by Application (2026-2031)

Table 64. Global Fusion Protein Biosimilars Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Fusion Protein Biosimilars Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Fusion Protein Biosimilars Revenue Market Share by Application (2020-2025)

Table 67. Global Fusion Protein Biosimilars Revenue Market Share by Application (2026-2031)

Table 68. Global Fusion Protein Biosimilars Price (US$/Unit) by Application (2020-2025)

Table 69. Global Fusion Protein Biosimilars Price (US$/Unit) by Application (2026-2031)

Table 70. Samsung Bioepis Company Information

Table 71. Samsung Bioepis Description and Business Overview

Table 72. Samsung Bioepis Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Samsung Bioepis Fusion Protein Biosimilars Product

Table 74. Samsung Bioepis Recent Developments/Updates

Table 75. Amgen Inc. Company Information

Table 76. Amgen Inc. Description and Business Overview

Table 77. Amgen Inc. Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Amgen Inc. Fusion Protein Biosimilars Product

Table 79. Amgen Inc. Recent Developments/Updates

Table 80. Pfizer Inc. Company Information

Table 81. Pfizer Inc. Description and Business Overview

Table 82. Pfizer Inc. Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Pfizer Inc. Fusion Protein Biosimilars Product

Table 84. Pfizer Inc. Recent Developments/Updates

Table 85. Sandoz (Novartis Division) Company Information

Table 86. Sandoz (Novartis Division) Description and Business Overview

Table 87. Sandoz (Novartis Division) Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Sandoz (Novartis Division) Fusion Protein Biosimilars Product

Table 89. Sandoz (Novartis Division) Recent Developments/Updates

Table 90. Coherus BioSciences Company Information

Table 91. Coherus BioSciences Description and Business Overview

Table 92. Coherus BioSciences Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Coherus BioSciences Fusion Protein Biosimilars Product

Table 94. Coherus BioSciences Recent Developments/Updates

Table 95. Celltrion Healthcare Company Information

Table 96. Celltrion Healthcare Description and Business Overview

Table 97. Celltrion Healthcare Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Celltrion Healthcare Fusion Protein Biosimilars Product

Table 99. Celltrion Healthcare Recent Developments/Updates

Table 100. Biocon Biologics Company Information

Table 101. Biocon Biologics Description and Business Overview

Table 102. Biocon Biologics Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Biocon Biologics Fusion Protein Biosimilars Product

Table 104. Biocon Biologics Recent Developments/Updates

Table 105. Dr. Reddy’s Laboratories Company Information

Table 106. Dr. Reddy’s Laboratories Description and Business Overview

Table 107. Dr. Reddy’s Laboratories Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Dr. Reddy’s Laboratories Fusion Protein Biosimilars Product

Table 109. Dr. Reddy’s Laboratories Recent Developments/Updates

Table 110. Mylan (Viatris Inc.) Company Information

Table 111. Mylan (Viatris Inc.) Description and Business Overview

Table 112. Mylan (Viatris Inc.) Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Mylan (Viatris Inc.) Fusion Protein Biosimilars Product

Table 114. Mylan (Viatris Inc.) Recent Developments/Updates

Table 115. 3SBio Inc. Company Information

Table 116. 3SBio Inc. Description and Business Overview

Table 117. 3SBio Inc. Fusion Protein Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. 3SBio Inc. Fusion Protein Biosimilars Product

Table 119. 3SBio Inc. Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Fusion Protein Biosimilars Distributors List

Table 123. Fusion Protein Biosimilars Customers List

Table 124. Fusion Protein Biosimilars Market Trends

Table 125. Fusion Protein Biosimilars Market Drivers

Table 126. Fusion Protein Biosimilars Market Challenges

Table 127. Fusion Protein Biosimilars Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Fusion Protein Biosimilars

Figure 2. Global Fusion Protein Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Fusion Protein Biosimilars Market Share by Type: 2024 & 2031

Figure 4. Cytokines Recombinant Protein Product Picture

Figure 5. Immunoglobin (Ig) Fusion Protein Product Picture

Figure 6. Global Fusion Protein Biosimilars Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Fusion Protein Biosimilars Market Share by Application: 2024 & 2031

Figure 8. Hospitals

Figure 9. Research Institute

Figure 10. Global Fusion Protein Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Fusion Protein Biosimilars Market Size (2020-2031) & (US$ Million)

Figure 12. Global Fusion Protein Biosimilars Sales (2020-2031) & (K Units)

Figure 13. Global Fusion Protein Biosimilars Average Price (US$/Unit) & (2020-2031)

Figure 14. Fusion Protein Biosimilars Report Years Considered

Figure 15. Fusion Protein Biosimilars Sales Share by Manufacturers in 2024

Figure 16. Global Fusion Protein Biosimilars Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Fusion Protein Biosimilars Players: Market Share by Revenue in Fusion Protein Biosimilars in 2024

Figure 18. Fusion Protein Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Fusion Protein Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Fusion Protein Biosimilars Sales Market Share by Country (2020-2031)

Figure 21. North America Fusion Protein Biosimilars Revenue Market Share by Country (2020-2031)

Figure 22. United States Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Fusion Protein Biosimilars Sales Market Share by Country (2020-2031)

Figure 25. Europe Fusion Protein Biosimilars Revenue Market Share by Country (2020-2031)

Figure 26. Germany Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Fusion Protein Biosimilars Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Fusion Protein Biosimilars Revenue Market Share by Region (2020-2031)

Figure 33. China Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. China Taiwan Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Latin America Fusion Protein Biosimilars Sales Market Share by Country (2020-2031)

Figure 41. Latin America Fusion Protein Biosimilars Revenue Market Share by Country (2020-2031)

Figure 42. Mexico Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Brazil Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Argentina Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Colombia Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Middle East and Africa Fusion Protein Biosimilars Sales Market Share by Country (2020-2031)

Figure 47. Middle East and Africa Fusion Protein Biosimilars Revenue Market Share by Country (2020-2031)

Figure 48. Turkey Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. UAE Fusion Protein Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Global Sales Market Share of Fusion Protein Biosimilars by Type (2020-2031)

Figure 52. Global Revenue Market Share of Fusion Protein Biosimilars by Type (2020-2031)

Figure 53. Global Fusion Protein Biosimilars Price (US$/Unit) by Type (2020-2031)

Figure 54. Global Sales Market Share of Fusion Protein Biosimilars by Application (2020-2031)

Figure 55. Global Revenue Market Share of Fusion Protein Biosimilars by Application (2020-2031)

Figure 56. Global Fusion Protein Biosimilars Price (US$/Unit) by Application (2020-2031)

Figure 57. Fusion Protein Biosimilars Value Chain

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions